ArticleCurrent neuropharmacology2023

Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study.

Emanuele D'Amico et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.